early-stage lung cuncer
Conditions
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria for the retrospective study: 1. Age >= 18 years; 2. Preoperative thin-section CT of the chest indicated that the maximum diameter of the target pulmonary nodule was = 18 years; 2. Preoperative thin-section CT of the chest indicated that the maximum diameter of the target pulmonary nodule was <= 2 cm, and a nodule resection was performed; 3. Preoperative imaging assessment showed no clear evidence of lymph node metastasis or distant metastasis; 4. The planned surgical specimen could obtain the tumor and adjacent/correlative tissue (without affecting the routine pathological diagnosis), meeting the requirements for research sample collection; 5. Postoperative pathological diagnosis was a lung adenocarcinoma spectrum lesion (including AAH/AIS/MIA/invasive adenocarcinoma) or highly suspected adenocarcinoma spectrum and could be included in the analysis (based on the final pathology); 6. Able to understand the research content and voluntarily participate, and sign a written informed consent form (if necessary, signed by a legal representative); 7. Able to complete postoperative follow-up and data collection (outpatient/telephone, etc.).
Exclusion criteria
Exclusion criteria: Retrospective study exclusion criteria: 1. Patients with confirmed lymph node metastasis or distant metastasis by postoperative pathology, or with other clear evidence of metastasis during the perioperative period; 2. Patients who received anti-tumor treatment (neoadjuvant chemotherapy/ radiotherapy/ immunotherapy/ targeted therapy, etc.) before the surgery, which may significantly affect the molecular characteristics of the tissue; 3. Non-adenocarcinoma spectra (such as squamous cell carcinoma, small cell carcinoma, metastatic tumors, etc.) or those with unclear diagnosis and cannot be classified; 4. Patients with concurrent or previous other malignant tumors (within the past 5 years, except for those with clear low-risk and cured cases), which the researcher considers may interfere with the determination of recurrence or the interpretation of molecular characteristics; 5. Patients with multiple nodules and unable to clearly match the target nodule with the corresponding specimen/imaging; 6. Missing or unverifiable key data: preoperative CT cannot be retrieved/CTR cannot be evaluated, missing pathological reports, inability to determine the follow-up outcome or the last 7. Specimen conditions do not meet the requirements: absence of FFPE wax blocks, incomplete tumor-carcinoma adjacent area, severe tissue necrosis/fixed poorly/ poor slice quality leading to inability to perform mIF or co-localization quantitative analysis; 8. Recurrence outcome determination has significant uncertainty: such as not following the standard follow-up and unable to verify the recurrence event through imaging/pathology/treatment records cross-validation. Inclusion criteria for the prospective study: 1. No lymph node metastasis or distant metastasis was confirmed before surgery or during or after surgery. 2. No other malignant tumors were concurrently or previously present (within the last 5 years), and the researchers believed that these conditions would affect the outcome or interpretation of molecular characteristics. 3. Antitumor treatments that significantly affect the tissue molecular characteristics were received before surgery, such as neoadjuvant chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other anti-tumor drug treatments. 4. The final pathology of the target lesion was not an adenocarcinoma spectrum disease and did not meet the study objectives (such as squamous cell carcinoma, small cell carcinoma, metastatic tumor, inflammatory/infectious lesion, etc.), or the pathological diagnosis was unclear and could not be included in the analysis. 5. There was no remaining tissue for study after routine pathological diagnosis, or the tissue was severely necrotic, had excessive ischemia time, or was contaminated, making it impossible to use for single-cell, spatial transcriptomics, or culture modeling. 6. The researchers judged that the subject was not suitable to participate or could not complete the follow-up due to severe comorbidities or unstable perioperative conditions (such as severe infection, severe cardiopulmonary dysfunction, etc.). 7. Inability to obtain valid informed consent (due to cognitive/communication disorders and no qualified legal representative), or explicit refusal to provide specimens and related data. 8. Other situations considered by the researchers as not suitable for inclusion (such as poor compliance, inability to obtain follow-up information, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The distribution characteristics of alveolar intermediate state cells in regions of tumor margins in different groups of consolidation tumor ratio?;The correlation between the proportion of alveolar intermediate state cells at the tumor margin and the invasive pathological features;The correlation between the proportion of alveolar intermediate state cells at the tumor margin and recurrence;The key ligand-receptor interaction axes between cancer cells, alveolar intermediate cells, and various components of the tumor microenvironment;The gene expression levels of alveolar epithelial cells;The protein expression level of alveolar epithelial cells;Transcriptional characteristics of alveolar epithelial cells; | — |
Countries
China
Contacts
Public ContactLunxu Liu
West China Hospital of Sichuan University
Outcome results
None listed